News
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform with the aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the utility of hematopoietic stem cell (HSC) transplant and in vivo genetic therapies.
Cimeio Therapeutics Presents Additional Proof-of-Concept Data for SCIP Platform
Poster session at ASGCT meeting describes key progress with shielded CD45 cells.
Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH
Preclinical data for Cimeio’s CD117- and CD123-shielded cells, and CD117 mAbs, demonstrate the potential of Cimeio’s SCIP platform to enable novel immunotherapy-based conditioning and post-transplant treatment approaches.
Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform
Cimeio Therapeutics today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs (SCIP) platform.
Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies.
Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies.